Oxford PharmaGenesis will support CISCRP in a new educational initiative to increase understanding and awareness of clinical research among minority urban communities. In order to find therapies that are effective for all, they have collaborated with CISCRP to sponsor an advertisement that emphasizes the critical importance of diversity among clinical study participants.
“Oxford PharmaGenesis will support CISCRP in a new educational initiative for patient diversity.“
CEO, Oxford PharmaGenesis, Chris Winchester, stated: “Diversity in clinical trials has never been more important than during a pandemic that disproportionately affects people from minorities. We at Oxford PharmaGenesis are proud to support CISCRP‘s campaign to increase the diversity of patients taking part in clinical trials.”